AXL-IN-13 (compound 6li) (50 or 100 mg/kg, p.o, 14 days) inhibits 4T1 tumor growth and metastasis[1].
AXL-IN-13 (25 mg/kg, p.o.) displays reasonable PK profiles with an AUC of 8410.21 ng/mL?h, a T1/2 value of 4.22 h, and an oral bioavailability (F) of 14.4%[1].
| Animal Model: | Xenograft model derived from highly metastatic 4T1 cells.[1] |
| Dosage: | 50 or 100 mg/kg |
| Administration: | Oral administration (p.o.) |
| Result: | Suppressed 4T1 tumor growth with a tumor growth inhibition (TGI) of 78.0 and 95.9% at 50 and 100 mg/kg, respectively.
Inhibited the phosphorylation of AXL.
Showed that liver is one of the most common sites of breast cancer metastasis.
|
| Animal Model: | Rats[1] |
| Dosage: | 5 mg/kg (i.v.), 25 mg/kg (p.o.) |
| Administration: | Intravenous injection (i.v.), oral administration (p.o.) |
| Result: | Pharmacokinetic parameters of AXL-IN-13 (Compound 6li).
| parameters | T1/2 (h) | Cmax (ng/mL) | AUClast | F (%) | |
| 5 mg/kg (i.v.) | 3.31 | 12280.44 | 11684.24 | | |
| 25 mg/kg (p.o.) | 4.22 | 887.75 | 8410.21 | 14.4 |
|
